BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Qyuns Therapeutics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Qyuns Therapeutics's drugs run\, 
 from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07879885-1951@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:HS-20137: Phase 2 readout est. (NCT07879885)
DESCRIPTION:HS-20137\, phase 2\, Psoriasis.\nStudy: An Open-label Study of 
 HS-20137 in Participants With Moderate-to-Severe Plaque Psoriasis\nEstimat
 ed primary completion: 1 March 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/hs-20137#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07879885
URL:https://assetmemo.bio/drug/hs-20137#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06844799-1951@assetmemo.bio
DTSTAMP:20261121T005017Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:HS-20137: Phase 3 readout est. (NCT06844799)
DESCRIPTION:HS-20137\, phase 3\, Psoriasis.\nStudy: A Study of HS-20137 in 
 Participants with Moderate-to-severe Plaque Psoriasis\nEstimated primary c
 ompletion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/hs-20137#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06844799
URL:https://assetmemo.bio/drug/hs-20137#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
